Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 7Carcinoma, Ovarian Epithelial 7Fallopian Tube Neoplasms 6Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Brenner Tumor 2Urinary Bladder Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Filgrastim 15Carboplatin 10Ifosfamide 9Doxorubicin 9Cyclophosphamide 9Peripheral Blood Stem Cell Transplantation 7pembrolizumab 6Radiotherapy 6Gemcitabine 6Temozolomide 5Etoposide 5Cisplatin 5Paclitaxel 4Docetaxel 4Amifostine 4aldesleukin 3aflibercept 3Trastuzumab 3Specimen Handling 3Radiosurgery 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Biopsy 3tislelizumab 2sodium thiosulfate 2selinexor 2pazopanib 2palbociclib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Erlotinib Hydrochloride × Gynecologic × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡